IRCT2017071128308N3CompletedPhase 2
The effect of adding Irbesartan to Pegylated Interferon-alpha-2a in Patients With HBeAg Negative Chronic Hepatitis B Co-infected With Hepatitis D
Vice chancellor for research Tehran University of Medical Sciences0 sites45 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 45
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 69 years (—)
- Sex
- All
Inclusion Criteria
- •chronic hepatitis B with HBsAg present at least 6 months before screening and infection with hepatitis D virus as anti-HDV positive antibodies for at least 3 months and positive for HDV-RNA in the screening period; HBeAg negative ; All women with fertility potential should have a negative pregnancy test before enrollment; ability to provide informed written consent to participate in the study.Exclusion criteria: untreated liver disease; co-infection with hepatitis C or HIV; Creatinine clearance <60 ml / min; Patients who are allergic to one of the Irbesartan components; Pregnancy and lactation; Patients with SBP <110 mm Hg or history of hypo tension at any time
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Recruiting
Not Applicable
Effect of on combination therapy with irbesartan and amlodipine besilate on clinical blood pressure, home blood pressure and blood pressure variability in hypertensive patients with chronic kidney diseaseHypertension with chronic kidney disease (CKD G1-G4)JPRN-UMIN000013213Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine30
Completed
Phase 4
Effects of the combination therapy of irbesartan and indapamide in chronik kidney disease with hypertensiochronick kidney disease with hypertensionJPRN-UMIN000010787Division of Nephrology, Department of Internal medicine, Jichi Medical University30
Active, not recruiting
Not Applicable
The effects of the association bindarit irbesartan versus irbesartan alone on albuminuria of patients with Diabetic Nephropathy. Placebo-controlled study. - NDPatients with type II diabetes with nephropathyMedDRA version: 9.1Level: SOCClassification code 10047065Term: Vascular disordersEUCTR2006-006191-38-ITANGELINI
Active, not recruiting
Phase 1
The effects of the association bindarit + irbesartan versus irbesartan alone on albuminuria of patients with Diabetic Nephropathy. Double-blind placebo-controlled study followed by an open extension phase.Diabetic Nephropathy (Type 2 diabetes)MedDRA version: 9.1Level: LLTClassification code 10061835Term: Diabetic nephropathyEUCTR2006-006191-38-SIAngelini Farmaceutici, ACRAF S.p.A.50
Active, not recruiting
Not Applicable
Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk - IMPROVEAlbuminuria in hypertensive subjects at increased cardiovascular risk.EUCTR2004-000022-75-LTBristol-Myers Squibb International Corporation615